Get App Open
In App
Credit Cards
Open App
you are here:
Success
Alert
Please select a Day.
Info

Marksans Pharma Ltd.

Sector : Healthcare | Industry : Pharmaceuticals & Drugs

50/100
165.04
-1.30 (-0.78%)

As on 30 Sep, 2025 | 03:56

Open Trading A/c
Day Range
164.25
169.80
L H
52 Week Range
162.51
358.70
L H
Volume
791,640
*
i

* BSE Market Depth (30 Sep 2025)

BUY SELL
QTY PRICE PRICE QTY
1 164.40 164.85 416
501 164.15 164.90 621
501 164.10 165.50 151
151 164.05 165.55 300
27 164.00 165.60 150
0 Total Total 0
Bid / Ask
0.00 / 0.00
50/100
164.85
-1.40 (-0.84%)

As on 30 Sep, 2025 | 04:01

Open Trading A/c
Day Range
164.50
169.00
L H
52 Week Range
162.45
358.50
L H
Volume
29,503
*
i

* BSE Market Depth (30 Sep 2025)

BUY SELL
QTY PRICE PRICE QTY
1 164.40 164.85 416
501 164.15 164.90 621
501 164.10 165.50 151
151 164.05 165.55 300
27 164.00 165.60 150
0 Total Total 0
Bid / Ask
0.00 / 0.00
NSE
MC Essentials
65% Pass
MC Technicals
i
This represents current trend.Click here for disclaimer.
MC Insights

Superior Financial Strength, High Growth Trend Stock at Reasonable Valuations

Financials
    Ownerships
      Industry Comparison
        Others
          Open 169.33
          Previous Close 166.34
          Volume 791,640.00
          Value (Lacs) 1,306.52
            VWAP 0.00
          Beta
          Mkt Cap (Rs. Cr.) 7,479
          High 169.80
          Low 164.25
          UC Limit 0.00
          LC Limit 0.00
          52 Week High 358.70
          52 Week Low 162.51
          Face Value 1.00
          All Time High 358.70
          All Time Low 1.08
          20D Avg Volume 1,086,804
          20D Avg Delivery(%) 45.65
          Book Value Per Share 50.34
          Dividend Yield 0.48
          TTM EPS See historical trend 7.73 (+4.94% YoY)
          TTM PE See historical trend 21.35 (Average PE)
          P/B See historical trend 3.28 (Average P/B)
          Sector PE 38.36

          Advanced Chart

          Click here to expand

          *Delayed by 20 seconds.

          Forecast                                                

          Earnings Forecast

          Actuals Estimates
          ANNUALLY 
          (Rs.) 

          Valuations

          Consensus Recommendations

          • Buy
          • Outperform
          • Hold
          • Underperform
          • Sell

          Hits/Misses

          QUARTERLY (Rs.)
          # of Beats
          # of Misses
          # of Inline
          # of Beats
          # of Misses
          # of Inline
          # of Beats
          # of Misses
          # of Inline

          MC Insights

          Stock Score

          50/100
          Superior Financial Strength, High Growth Trend Stock at Reasonable Valuations

          Get detailed analysis with Moneycontrol Stock Insights.

          Get detailed analysis with Moneycontrol Stock Insights.

          Price
          • 53.99% away from 52 week high

          Financials
          Piotroski Score
          i

          indicates

          Industry Comparison
          • Market Cap - Above Median

          Shareholding Pattern
          • Promoter holding remains unchanged at 43.87% in Jun 2025 qtr.

          MC Technicals

          TECHNICAL RATING
          i
          This represents current trend.
          Click here for disclaimer.
          Moving Averages --
          Technical Indicators --
          Moving Averages Crossovers --

          Pivot levels

          Type R1 R2 R3 PP S1 S2 S3
          Classic - - - - - - - - - - - - - -
          Fibonacci - - - - - - - - - - - - - -
          Camarilla - - - - - - - - - - - - - -

          Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.

          Pivot levels

          R1 - - Pivot
          - -
          S1 - -
          R2 - - S2 - -
          R3 - - S3 - -

          Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.

          Moving Averages
          Days
          5 - -
          10 - -
          20 - -
          50 - -
          100 - -
          200 - -
          TECHNICAL RATING
          i
          This represents current trend.
          Click here for disclaimer.
          Moving Averages --
          Technical Indicators --
          Moving Averages Crossovers --

          Pivot levels

          Type R1 R2 R3 PP S1 S2 S3
          Classic - - - - - - - - - - - - - -
          Fibonacci - - - - - - - - - - - - - -
          Camarilla - - - - - - - - - - - - - -

          Note : Support and Resistance level for the week, calculated based on price range of the previous trading week.

          Pivot levels

          R1 - - Pivot
          - -
          S1 - -
          R2 - - S2 - -
          R3 - - S3 - -

          Note : Support and Resistance level for the week, calculated based on price range of the previous trading week.

          Moving Averages
          Days
          TECHNICAL RATING
          i
          This represents current trend.
          Click here for disclaimer.
          Moving Averages --
          Technical Indicators --
          Moving Averages Crossovers --

          Pivot levels

          Type R1 R2 R3 PP S1 S2 S3
          Classic - - - - - - - - - - - - - -
          Fibonacci - - - - - - - - - - - - - -
          Camarilla - - - - - - - - - - - - - -

          Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.

          Pivot levels

          R1 - - Pivot
          - -
          S1 - -
          R2 - - S2 - -
          R3 - - S3 - -

          Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.

          Moving Averages
          Days

          Price and Volume

          Price Performance
          1 Week
          --%
          1 Month
          --%
          3 Months
          --%
          YTD
          --%
          1 Year
          --%
          3 Years
          --%
          Volume Analysis
          • Volume
          • Delivery

          SEASONALITY ANALYSIS

          9 out of 15 years Marksans Pharma has given negative returns in October.

          Month Max. Positive Change(%) Avg. Positive Change(%) Max. Negative Change(%) Avg. Negative Change(%) Average Change(%)
          October 9.39% (2019) 5.54% -23.02% (2009) -5.59% -1.14%

          Forum

          Community Sentiments

          • 100% BUY
          • 0% SELL
          • 0% HOLD
          100%
          of moneycontrol users recommend buying Marksans Pharma

          What's your call on Marksans Pharma today?

          Read 3 investor views

          BUY SELL HOLD

          Broker Research

          No Data For Broker Research.

          Deals

          11 Jun, 2025

          Orbimed Asia Iv Mauritius Fvci Limited

          Qty 10273443 Price 249.95 % Traded 2.15
          11 Jun, 2025

          Unifi Capital Private Limited -blended Rangoli

          Qty 3247600 Price 249.95 % Traded 0.68
          11 Jun, 2025

          Unifi Blend Fund 2

          Qty 3000000 Price 249.95 % Traded 0.63
          11 Jun, 2025

          Societe Generale

          Qty 920184 Price 249.95 % Traded 0.19
          11 Jun, 2025

          Bandhan Mutual Fund

          Qty 600000 Price 249.95 % Traded 0.13
          11 Jun, 2025

          Unifi Capital Private Limited

          Qty 594000 Price 249.95 % Traded 0.12
          11 Jun, 2025

          Unifi Bcad Fund

          Qty 560000 Price 249.95 % Traded 0.12
          11 Jun, 2025

          Subhkam Ventures I Private Limited

          Qty 537485 Price 249.95 % Traded 0.11

          *Transaction of a minimum quantity of 500,000 shares or a minimum value of Rs 5 crore.

          28 Jul, 2025

          Unifi Capital Private Limited

          Qty 7241309 Price 231.5 % Traded 1.63
          11 Jun, 2025

          Orbimed Asia Iv Mauritius Fvci Limited

          Qty 10273443 Price 249.95 % Traded 2.15
          11 Jun, 2025

          Unifi Capital Private Limited -blended Rangoli

          Qty 3247600 Price 249.95 % Traded 0.68
          11 Jun, 2025

          Unifi Blend Fund 2

          Qty 3000000 Price 249.95 % Traded 0.63
          20 Sep, 2024

          Ubs Principal Capital Asia Limited

          Qty 3401630 Price 317.22 % Traded 0.75
          20 Sep, 2024

          Vanguard Total International Stock Index Fund

          Qty 2697280 Price 316.85 % Traded 0.59
          20 Sep, 2024

          Graviton Research Capital Llp

          Qty 2451180 Price 305.27 % Traded 0.52
          20 Sep, 2024

          Graviton Research Capital Llp

          Qty 2451180 Price 305.27 % Traded 0.52

          *A bulk deal is a trade where total quantity of shares bought or sold is more than 0.5% of the equity shares of a company listed on the exchange.

          Financials

          • Revenue
          • Net Profit
          • EPS
          • BVPS
          • ROE
          • Debt to Equity
          • Revenue
          • Net Profit
          • EPS
          • BVPS
          • ROE
          • Debt to Equity

          Shareholding

          PEERS

          Company Name Price % Chg MCap(Cr) TTM PE P/B ROE(%) 1 Yr Perform(%) Net Profit(Rs.) Net Sales(Rs.) Debt to Equity
          Marksans Pharma 165.04 -0.78 7,479.01 21.35 3.28 15.42 -44.60 382 2,622 0.01
          Sun Pharma 1,594.30 0.31 382,525.97 36.88 5.53 15.13 -17.25 10,980 52,578 0.03
          Divis Labs 5,689.50 -0.14 151,038.35 65.49 11.01 14.63 4.52 2,191 9,360 0.00
          Torrent Pharma 3,603.20 0.46 121,948.66 60.92 16.25 25.17 6.08 1,911 11,516 0.40
          Cipla 1,503.30 1.03 121,431.42 22.52 4.28 16.90 -9.12 5,291 27,547 0.00

          About the Company

          Marksans Pharma Limited together with its subsidiaries operates as an integrated international pharmaceutical company. The Companys business is distribution of pharmaceutical products. It is actively engaged in research and development (R&D) and offering contract research and manufacturing services (CRAMS) to global pharmaceutical companies. The R&D capability of the Company includes dossier development service, formulation development and specified drug delivery system. The Companys domestic formulation business is the specialty division, which mainly focuses on oncology and critical care therapy. The brands of this division are MARKPARIN and EPIGROF. EPIGROF is also being supplied to hospitals and other burns and trauma care institutes. Cerebella division is the specialty division marketing drugs meant for lifestyle diseases, neuro and psychiatric therapy. The brands of this division are BAZZY, CITOFAST, GABELLA, GABELLA M, XENOTRIL, which are the main contributors of sales.
          {"success":1,"data":{"address":{"address1":"11th Floor, Grandeur,","address2":"Veera Desai Extension Road,,Oshiwara, Andheri (West),","city":"Mumbai","state":"Maharashtra","pincode":"400053","telephone1":"022-40012000","telephone2":"","fax1":"022-40012011","fax2":"","email":"companysecretary@marksanspharma.com","web":"http:\/\/www.marksanspharma.com"},"management":[{"name":"Mark Saldanha","designation":"Chairman & Managing Director"},{"name":"Sandra Saldanha","designation":"Whole Time Director"},{"name":"Varddhman V Jain","designation":"Whole Time Director"},{"name":"Sunny Sharma","designation":"Non Executive Director"},{"name":"Srinivas Mishra","designation":"Independent Director"}],"registrars":{"name":"Bigshare Services Pvt. Ltd.","address1":"S6-2, 6th Floor, Pinnacle Business Park,\nNext to A","address2":"","address3":"","address4":"","telephone":"022-62638200","fax":"022-62638261","email":"investor@bigshareonline.com","internet":"http:\/\/www.bigshareonline.com","city":"Mumbai","state":"Maharashtra","pincode":"400093"},"listing":[{"name":"BSE 100","value":"No"},{"name":"BSE 200","value":"No"},{"name":"SENSEX","value":"No"},{"name":"CNX MIDCAP 200","value":"No"},{"name":"NIFTY 50","value":"No"},{"name":"BSE 500","value":"No"},{"name":"Nifty 200","value":"No"}],"details":{"bseId":"524404","nseId":"MARKSANS","series":"EQ","isinid":"INE750C01026"}}}
          • Registered Office

          • Registrars

          • Management

            • Mark Saldanha

              Chairman & Managing Director

            • Sandra Saldanha

              Whole Time Director

            • Varddhman V Jain

              Whole Time Director

            • Sunny Sharma

              Non Executive Director

            • Srinivas Mishra

              Independent Director

          • Included In

            • BSE 100

              No

            • BSE 200

              No

            • SENSEX

              No

            • CNX MIDCAP 200

              No

            • NIFTY 50

              No

            • BSE 500

              No

            • Nifty 200

              No

          • Details

            • BSE:

              524404

            • NSE:

              MARKSANS

            • Series

              EQ

            • ISIN

              INE750C01026